GlobalData, the industry analysis specialist, has released its new report, “Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Toxoplasmosis Therapeutics market. The report identifies the key trends shaping and driving the global Toxoplasmosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Toxoplasmosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Toxoplasmosis therapeutics pipeline assessment and market forecasts to 2019
1. Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to
2019
Summary
GlobalData, the industry analysis specialist, has released its new report, “Toxoplasmosis
Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential
source of information and analysis on the global Toxoplasmosis Therapeutics market. The report
identifies the key trends shaping and driving the global Toxoplasmosis Therapeutics market. The
report also provides insights on the prevalent competitive landscape and the emerging players
expected to significantly alter the market positioning of the current market leaders. Most
importantly, the report provides valuable insights on the pipeline products within the global
Toxoplasmosis Therapeutics sector. This report is built using data and information sourced from
proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team
of industry experts.
Scope
The report provides information on the key drivers and challenges of the Toxoplasmosis
Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Toxoplasmosis
Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being
developed and emerging trends by seven key markets. Pipeline candidates fall under major
therapeutic classes.
- Analysis of the current and future competition in the seven key countries Toxoplasmosis
Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet
needs and the implications for the Toxoplasmosis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Toxoplasmosis Therapeutics
market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline
products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global
Toxoplasmosis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market
2. segments and companies likely to impact the global Toxoplasmosis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape
and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-
strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that
present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Toxoplasmosis Therapeutics market landscape? – Identify,
understand and capitalize.
Buy Your Copy of Report: http://www.reportsnreports.com/reports/174214-toxoplasmosis-
therapeutics-pipeline-assessment-and-market-forecasts-to-2019.html
Report Details:
Published: July 2012
Price Single User License: US $ 3995 Price Corporate User License: US $ 11895
Table of Contents
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Toxoplasmosis Therapeutics - Introduction 6
2.1 Disease Overview 6
2.1.1 Types of Toxoplasma gondii Strain 7
2.1.2 Life Cycle and Transmission 7
2.2 Epidemiology 7
2.2.1 Historic Epidemiology (2006–2011) 8
2.2.2 Forecast Epidemiology (2011–2019) 9
2.3 Etiology 10
2.3.1 Food-borne Transmission 10
2.3.2 Congenital Transmission 10
2.3.3 Zoonotic Transmission 10
2.3.4 Rare Instances of Transmission 10
2.4 Pathophysiology 10
2.5 Signs and Symptoms 11
2.6 Commonly Used Diagnostic Tests 12
2.6.1 Types of Diagnostic Test 12
2.7 Treatment and Management Options for Toxoplasmosis 13
3. 2.7.1 Management of Toxoplasmosis Infection during Gestation 14
2.7.2 Congenital Toxoplasmosis 14
2.7.3 Ocular Toxoplasmosis 15
2.7.4 Toxoplasmosis in Immunocompetent Patients 15
2.8 GlobalData Pipeline Report Guidance 16
3 Toxoplasmosis Therapeutics - Market Characterization 17
3.1 Toxoplasmosis Therapeutics Market Size (2006–2011) – Global 17
3.2 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Global 19
3.3 Toxoplasmosis Therapeutics Market Size (2006–2011) – The US 20
3.4 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – The US 21
3.5 Toxoplasmosis Therapeutics Market Size (2006–2011) – France 22
3.6 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – France 23
3.7 Toxoplasmosis Therapeutics Market Size (2006–2011) – Germany 24
3.8 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Germany 25
3.9 Toxoplasmosis Therapeutics Market Size (2006–2011) – Italy 26
3.10 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Italy 27
3.11 Toxoplasmosis Therapeutics Market Size (2006–2011) – Spain 28
3.12 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Spain 29
3.13 Toxoplasmosis Therapeutics Market Size (2006–2011) – The UK 30
3.14 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – The UK 31
3.15 Toxoplasmosis Therapeutics Market Size (2006–2011) – Japan 32
3.16 Toxoplasmosis Therapeutics Market Forecast (2011–2019) – Japan 33
3.17 Drivers and Barriers for the Toxoplasmosis Therapeutics Market 34
3.17.1 Drivers for the Toxoplasmosis Therapeutics Market 34
3.17.2 Barriers for the Toxoplasmosis Therapeutics Market 34
3.18 Opportunity and Unmet Need Analysis 35
3.19 Key Takeaway 36
4 Toxoplasmosis Therapeutics - Competitive Assessment 37
4.1 Overview 37
4.2 Strategic Competitor Assessment 37
4.3 Product Profiles of the Marketed Products in the Toxoplasmosis Therapeutics Market 38
4.3.1 Daraprim (pyrimethamine) 38
4.3.2 Spiramycin 39
4.3.3 Sulfadiazine 39
4.3.4 Folinic Acid 40
4.4 Key Takeaway 40
5 Toxoplasmosis Therapeutics - Pipeline Assessment 41
5.1 Overview 41
5.2 Strategic Pipeline Assessment 41
5.2.1 Toxoplasmosis Therapeutics – Phase III Clinical Pipeline 41
5.3 Key Takeaway 41
6 Toxoplasmosis Therapeutics - Clinical Trial Mapping 42